Table 1.

List of clinical trials that administrate immune checkpoint inhibitors for COVID-19 patients

Identifier	Inclusion criteria	Experiment treatment	Control treatment	The experimental agent mechanism of action
NCT04413838	Obese* individuals with COVID-19 infection	Nivolumab††	Routine standard of care	-Anti-PD1
NCT04356508	Individuals with mild** or moderate*** COVID-19 infection	Nivolumab††	Routine standard of care	-Anti-PD1
NCT04268537	Individuals with COVID-19 infection, lymphopenia† and Severe respiratory failure‡	-PD-1 blocking antibody†† -thymosin††	Routine standard of care	-Anti-PD1 -stimulate T-cells production
NCT04333914	Individuals with COVID-19 infection and advanced or metastatic hematological or solid tumor	-GNS561†† -Monalizumab†† -Avdoralimab††	Routine standard of care	-autophagy inhibitor -anti-NKG2A -anti-C5aR

* BMI≥30 kg/m2

**symptoms with or without lung infiltrates on chest X-Ray or CT imaging

***lung infiltrates with evidence of type 1 respiratory failure

†< 0. 6x 109/L

‡ PaO2/FiO2 < 200 mmHg and supported by positive pressure mechanical ventilation

†† +Routine standard of care